Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nanomix Corp Public Investor Deck
• Leader in decentralized testing – large, fast-growing market
• Need for decentralized testing is reinforced by COVID-19 experience
• Most Advanced Mobile Diagnostic System
• One instrument for many different tests
• Lab quality results in an easy-to-use system
• Robust and connected for use in ambulance, ER, assisted living, Dr. office, events, airports…
• Deep Technical Expertise and IP
• All technology developed and wholly owned by Nanomix
• 29 issued and pending patents
• Market Ready Critical Infection Panel – a game changer for clinical diagnosis
• The ONLY portable, rapid PCT assay
• Drives unique rapid testing solutions for sepsis / pneumonia
Only POC multiplexed panel for PCT, CRP, & LAC
• Results in 11 minutes
• Lab quality results
Innovative Diagnostic Platforms Create Value
INNOVATOR ........... ACQUIRER
ALERE ............ ABBOTT POC $5.3B
CEPHEID(MDx)...... DANAHER $3.9
BABAXIS(VET)..... ZOETIS $1.8B
https://content.equisolve.net/bostonti/media/00497b4a58e1e32dbd7ce23c9923a2d7.pdf
My first post here. There was a large block purchased at $6 at around 15:35 anyone seen it? How many share was it? TIA
NLST Long
David vs Goliaths aka Netlist,Inc. vs Google and others...
The netlist story really took off in July when the US Court of Appeals for the Federal Circuit affirmed the U.S. Patent Trial and Appeal Board’s decision upholding the validity of Netlist’s U.S. 7,619,912 (‘912) patent that applies to DDR server memory modules. The decision is final and binding on future cases and represents a resounding win for Netlist.
The (‘912) patent is a seminal patent; an invention so impactful that it creates or shifts the technology space.
This ruling has much larger implications than just GOOG which will more than likely set the tone for other settlements long overdue here.
Since last year the case has been progressing forward and today is the day for the joint letter to the court on discovery if the parties did not come to terms! If they could not come to terms the letter explaining both parties’ position on discovery process no longer than 10 pages is to be submitted today! Once the letter is submitted Judge Spero will decide the discovery process going forward. CA courts favor broad Discovery! The Judge already told Google they would probably not like the result if he had to decide.
https://microcapdaily.com/netlist-inc-otcmkts-nlst-powerful-runner-as-lawsuit-over-912-seminal-patent-moves-forward/132077/
Check Video here: https://www.reddit.com/r/NLST/comments/odjen7/great_vid_500_views_on_july_3rd/?utm_medium=android_app&utm_source=share
David vs Goliaths aka Netlist,Inc. vs Google and others...
The netlist story really took off in July when the US Court of Appeals for the Federal Circuit affirmed the U.S. Patent Trial and Appeal Board’s decision upholding the validity of Netlist’s U.S. 7,619,912 (‘912) patent that applies to DDR server memory modules. The decision is final and binding on future cases and represents a resounding win for Netlist.
The (‘912) patent is a seminal patent; an invention so impactful that it creates or shifts the technology space.
This ruling has much larger implications than just GOOG which will more than likely set the tone for other settlements long overdue here.
Since last year the case has been progressing forward and today is the day for the joint letter to the court on discovery if the parties did not come to terms! If they could not come to terms the letter explaining both parties’ position on discovery process no longer than 10 pages is to be submitted today! Once the letter is submitted Judge Spero will decide the discovery process going forward. CA courts favor broad Discovery! The Judge already told Google they would probably not like the result if he had to decide.
https://microcapdaily.com/netlist-inc-otcmkts-nlst-powerful-runner-as-lawsuit-over-912-seminal-patent-moves-forward/132077/
Check Video here: https://www.reddit.com/r/NLST/comments/odjen7/great_vid_500_views_on_july_3rd/?utm_medium=android_app&utm_source=share
David vs Goliaths aka Netlist,Inc. vs Google and others...
The netlist story really took off in July when the US Court of Appeals for the Federal Circuit affirmed the U.S. Patent Trial and Appeal Board’s decision upholding the validity of Netlist’s U.S. 7,619,912 (‘912) patent that applies to DDR server memory modules. The decision is final and binding on future cases and represents a resounding win for Netlist.
The (‘912) patent is a seminal patent; an invention so impactful that it creates or shifts the technology space.
This ruling has much larger implications than just GOOG which will more than likely set the tone for other settlements long overdue here.
Since last year the case has been progressing forward and today is the day for the joint letter to the court on discovery if the parties did not come to terms! If they could not come to terms the letter explaining both parties’ position on discovery process no longer than 10 pages is to be submitted today! Once the letter is submitted Judge Spero will decide the discovery process going forward. CA courts favor broad Discovery! The Judge already told Google they would probably not like the result if he had to decide.
https://microcapdaily.com/netlist-inc-otcmkts-nlst-powerful-runner-as-lawsuit-over-912-seminal-patent-moves-forward/132077/
Check Video here: https://www.reddit.com/r/NLST/comments/odjen7/great_vid_500_views_on_july_3rd/?utm_medium=android_app&utm_source=share
David vs Goliath aka Netlist, Inc. vs Google
Netlist, Inc. (OTCMKTS: NLST) Powerful Runner as Lawsuit Over (‘912) Seminal Patent Moves Forward
https://microcapdaily.com/netlist-inc-otcmkts-nlst-powerful-runner-as-lawsuit-over-912-seminal-patent-moves-forward/132077/
NLST Progress/Thread : https://www.reddit.com/r/NLST/new/
David vs Goliath aka Netlist, Inc. vs Google
Netlist, Inc. (OTCMKTS: NLST) Powerful Runner as Lawsuit Over (‘912) Seminal Patent Moves Forward
https://microcapdaily.com/netlist-inc-otcmkts-nlst-powerful-runner-as-lawsuit-over-912-seminal-patent-moves-forward/132077/
NLST Progress/Thread : https://www.reddit.com/r/NLST/new/
David vs Goliath aka Netlist, Inc. vs Google
Netlist, Inc. (OTCMKTS: NLST) Powerful Runner as Lawsuit Over (‘912) Seminal Patent Moves Forward
https://microcapdaily.com/netlist-inc-otcmkts-nlst-powerful-runner-as-lawsuit-over-912-seminal-patent-moves-forward/132077/
NLST Progress/Thread : https://www.reddit.com/r/NLST/new/
David vs Goliath aka Netlist, Inc. vs Google
Netlist, Inc. (OTCMKTS: NLST) Powerful Runner as Lawsuit Over (‘912) Seminal Patent Moves Forward
https://microcapdaily.com/netlist-inc-otcmkts-nlst-powerful-runner-as-lawsuit-over-912-seminal-patent-moves-forward/132077/
NLST Progress/Thread : https://www.reddit.com/r/NLST/new/
David vs Goliath aka Netlist, Inc. vs Google
Netlist, Inc. (OTCMKTS: NLST) Powerful Runner as Lawsuit Over (‘912) Seminal Patent Moves Forward
https://microcapdaily.com/netlist-inc-otcmkts-nlst-powerful-runner-as-lawsuit-over-912-seminal-patent-moves-forward/132077/
NLST Progress/Thread : https://www.reddit.com/r/NLST/new/
David vs Goliath aka Netlist, Inc. vs Google
Netlist, Inc. (OTCMKTS: NLST) Powerful Runner as Lawsuit Over (‘912) Seminal Patent Moves Forward
https://microcapdaily.com/netlist-inc-otcmkts-nlst-powerful-runner-as-lawsuit-over-912-seminal-patent-moves-forward/132077/
NLST Progress/Thread : https://www.reddit.com/r/NLST/new/
So predictable :D
Exactly why $mart money loading action is in order :D
Very Insightful. Thank you!
Does this mean more money next Q?
From SEC 10-K
NOTE 19. SUBSEQUENT EVENTS
Sale of New Jersey Net Operating Loss and Research and Development Tax Credit
In April 2021, Elite Laboratories Inc., a wholly owned subsidiary of Elite Pharmaceuticals Inc. received final approval from the New Jersey Economic Development Authority for the sale of net tax benefits of $798,889 relating to New Jersey net operating losses and net tax benefits of $58,490, relating to research and development tax credits. The Company sold the net tax benefits approved for sale at a transfer price equal to ninety three and one half cents for every benefit dollar and incurred transaction fees of $12,861, resulting in net proceeds to the Company of $788,789.
SEC Form 8-k Filed. Closing of merger - a matter of days now :)
Mr. Cheng already resigned as CEO and Director.
Yup! Farther supported by recently filed SEC 8-K
On April 30, 2021, Boston Therapeutics, Inc. (the “Company”) received a short-term loan in the aggregate principal amount of $500,000 from Gold Blaze Limited Vistra Corporate Services (“Gold Blaze”). Gold Blaze is a British Virgin Island company. Conroy Chi-Heng Cheng, the sole executive officer and director of the Company, a director and beneficial owner of Gold Blaze.
To evidence the loan, the Company issued Gold Blaze a promissory note (the “Gold Blaze Note”) in the aggregate principal amount of $500,000. The Gold Blaze Note is a secured obligation of the Company and is not convertible into equity securities of the Company. Principal and interest under the Gold Blaze Note is due and payable December 31, 2021. Interest accrues on the Gold Blaze Note at the rate of 5.0% per annum. The Gold Blaze Note contains terms and events of default customary for similar transactions. If the Company effects a subsequent financing of its equity, debt, equity-linked, and/or debt-linked securities (including any combination thereof) (a “Subsequent Financing”), Gold Blaze may elect, in its sole discretion, to exchange all or some of the Gold Blaze Note for any securities issued in a Subsequent Financing on a $1.00 for $1.00 basis based on the outstanding principal amount of the Gold Blaze Note, along with any liquidated damages, accrued but unpaid and other amounts owing thereon, and the effective price at which such securities are to be sold in such Subsequent Financing.
As previously reported, on January 26, 2021, the Company, BTHE Acquisition Inc., a California corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Nanomix, Inc., a California corporation (“Nanomix”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Nanomix, with Nanomix continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the “Merger”). The Company used the net proceeds from the Gold Blaze Note to provide a $500,000 loan to Nanomix in consideration of a 10% Promissory Note issued by Nanomix to the Company (the “Nanomix Note”) due and payable upon the earlier of (i) the failure to consummate the Merger, (ii) the termination of the Merger Agreement and (iii) June 11, 2021; provided, however, that upon the consummation of the Merger, the outstanding principal amount of this Note and all accrued and unpaid interest thereon shall be assumed by the Maker and become payable upon demand upon five days prior written notice from the Holder.
https://www.sec.gov/Archives/edgar/data/1473579/000121390021025831/ea140759-8k_bostonthera.htm
Whoa! 4.3 milly vol activity today. What's going on here? Did I miss something?
Fighting for Our Lives
At the first signs that a pandemic would be radically disrupting our lives, some of the East Bay’s brightest minds got busy. From creating effective coronavirus tests to contributing to vaccine development, local thought leaders brought their A games to the fight against COVID-19.
RAPID RESULTS
When David Ludvigson’s mother moved into an assisted living facility, he asked about its COVID-19 testing process. Staff and residents’ samples were sent to a lab, he learned, with results coming back two or three days later.
“When you’re dealing with a critical infection, two to three days make for very difficult patient management,” says Ludvigson, CEO of Nanomix, a developer of mobile diagnostics in Emeryville. “We said, why wait two to three days? Why not wait 10 or 15 minutes? Then you know exactly what to do with that patient at that point.”
Nanomix has expertise developing quick, highly accurate diagnostic tests. In 2014, as Ebola spread in West Africa, Nanomix helped to develop a prototype system to identify Ebola via a 10-minute blood test. “We knew that our system would work well with highly contagious viruses,” Ludvigson says. “And we had some confidence that we could do rapid product development, ?because we had done it in the past.”
With a platform already in place, Nanomix?had a significant head start. It developed?a 10-minute blood test to detect the presence of antibodies in people who’ve ?recovered from COVID-19. It also developed a 15-minute nasal swab test for detecting the active virus in symptomatic people.
In both tests, the patient’s sample is put on a single-use cartridge, which is placed into a handheld reader. “You get an answer, positive or negative,” Ludvigson says. “And the person doing the test does not have to be a trained medical person.” So the technology?can be used nearly anywhere—in an ?ambulance, an assisted living facility, or ?your local pharmacy—with results being ?sent via Bluetooth to whoever needs them.
Recently, the company completed the FDA filing for its antigen test, which was named a finalist in the Xprize Rapid COVID Testing competition. “People were excited to work on potential products that could help,” Ludvigson says. “Now [we’ll be] shifting to the next challenge, which ?is producing and delivering a lot of product. The challenges don’t end.”
https://nano.com/news.php
Standard SEC Protocol: "QUIET PERIOD" is being enforced during this merging process. Stay tune.
Nanomix, Inc. https://nano.com/ merging with Boston Therapeutics (otcpink & SEC Filer: BTHE)
https://www.sec.gov/Archives/edgar/data/1473579/000121390021006198/ea134438ex2-1_boston.htm
Got goosebumps when I found out that BTHE CEO Conroy Cheng has been involved with Nanomix since 2017.
EMERYVILLE, Calif., Nov. 9, 2017 /PRNewswire/ -- Nanomix, Inc., a developer of next-generation, mobile, point-of-care diagnostics, today announced the completion of a comprehensive equity investment and business collaboration with the World Technology East 2, RedPharm Biotechnology Ltd., and the associated entities in Hong Kong, China and the European Community. The relationship focuses on the use and deployment of Nanomix products and technology throughout Asia for human applications and worldwide veterinary applications in farm animal, companion animal, and wildlife management and control.
"As part of our integrated healthcare business strategy, we are investing in these advanced healthcare products and technologies to help meet the demand for high quality, precise, immediate and available healthcare diagnosis at an affordable cost for all people in the China and Asia sphere," said Conroy Cheng, Director of World Technology East and RedPharm Biotechnology Ltd. "The Nanomix technology and allied products will deliver critical advanced diagnostic tools and information for multiple markets."
https://www.prnewswire.com/news-releases/nanomix-announces-equity-financing-and-collaboration-with-hong-kong-beijing-based-world-technology-east-and-redpharm-biotechnology-companies-300552518.html
Nanomix is the leader in the development of mobile point-of-care (POC) diagnostics, with a handheld testing platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical for clinical decision-making and improved patient care.
Today’s model of centralized healthcare services works for patients who can access hospitals and whose conditions can be adequately addressed in hours or days rather than minutes. But many medical decisions require faster intervention. Advances in mobile communications and point-of-care platforms are driving a decentralization of disease diagnosis, improving our ability to treat patients faster, even without a visit to the hospital.
Our products are designed to improve healthcare delivery by bringing the most important diagnostic information to the point of initial patient interaction, whether in the hospital or in settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more. This kind of testing supports treating patients where they are as well as choosing the right treatment faster.
Nanomix was founded in 2000 by UC Berkeley professors and award-winning physicists at Lawrence Berkeley National Laboratory, Marvin L. Cohen and Alex Zettl. Today, our company is poised to become the premier provider of the next generation of rapid point-of-care diagnostics. The POC testing market is currently valued at approximately $20 billion.
Our first assay addresses the critical need to provide more comprehensive information to clinicians faster to aid in the diagnosis of sepsis and other critical infections. We are developing a deep pipeline of other high-value tests where the rapid availability of high-quality diagnostic information can improve patient outcomes, including:
>>> Acute kidney injury
>>> SARS-CoV-2 antigen and antibody tests for COVID-19
>>> Rapid multi-application cardiac testing
>>> Stroke
>>> Traumatic brain injury
In 2017, Nanomix formed a collaboration with World Technology East 2, RedPharm Biotechnology Ltd, and associated entities in Hong Kong, China, and the European Community. Our partnership focuses on the use and deployment of Nanomix products and technology throughout Asia for human applications and worldwide veterinary applications in farm animal, companion animal, and wildlife management and control.
https://nano.com/nanomix.php
Nice! I hope this merger succeeds. You're right! The potential is huge! Not to mention Nanomix just filed EUA with the FDA for their Covid testing product. What a way to start trading under a new name and announce an EUA approval when the time comes. Congrats with your new shares! Good luck to us.
To think of uplisting to a major exchange is in my opinion a valid reason to execute a rs. The merging company is established with marketed products and it is wise to be in a major exchange like Nasdaq or Amex to gain more exposure to institutional investors.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On January 26, 2021, holders of 85.8% of the voting power of our capital stock acted by written consent in lieu of a meeting to approve an amendment to the Company’s Certificate of Incorporation, as amended, effecting a one-for-173 reverse split of the Company’s common stock and to change our corporate name from Boston Therapeutics, Inc. to “Nanomix Holdings, Inc.” The name change and reverse stock split are subject to approval by FINRA.
https://www.sec.gov/Archives/edgar/data/1473579/000121390021006198/ea134438-8k_bostontherap.htm
Oh boy! Glad you came. I thought I'm the only one left in the table. LOL
EMERYVILLE, Calif., February 9, 2021 Nanomix Submits Emergency Use Authorization Request to FDA for Rapid Antigen Panel to Detect COVID-19
Portable, handheld test produces laboratory-quality results in 15 minutes in any setting to increase access and availability of COVID-19 testing
Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for the eLab® COVID-19 rapid antigen test. The assay runs on the portable Nanomix eLab analyzer, which provides results in just 15 minutes and can be used in a wide range of settings, including hospitals, nursing homes, assisted living facilities, urgent care centers, and emergency medical care.
The Nanomix eLab platform and COVID-19 rapid antigen test will enable medical professionals, emergency workers, and employers to test individuals for antigens that indicate COVID-19 infection. The assay uses a nasal swab sample that can be self-administered, and is designed to complement existing test methods by expanding access to rapid, laboratory-quality results outside of hospital facilities.
“While the global healthcare community has made tremendous progress in COVID-19 testing, there is still significant need for rapid, accurate, and affordable testing that can be conducted outside of laboratory settings,” said David Ludvigson, president and CEO of Nanomix. “By completing this EUA filing, we are one step closer to making our antigen test available to help address this remaining gap.”
Nanomix previously validated and made available a rapid test for IgG and IgM antibodies that also runs on the eLab analyzer, and indicates past exposure to the SARS-CoV-2 virus.
Nanomix developed both the COVID-19 antigen and antibody assays in part with funding from BARDA.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures under Contract No. 75A50120C00060.
https://nano.com/articles/2021-02-09-Nanomix-Submits-Emergency-Use.php
Nasdaq Uplisting upon rs maybe in the cards as well?
BTHE merging with NanoMix, Inc. https://nano.com/
Covid Diagnostic Play here we come!!!
WOW!!!MERGER!!!...MERGER!!! in the works! THIS IS GOING TO BE A COVID 19 TESTING PLAY! Boston Therapeutics (BTHE) is merging with NanoMix, Inc. NanoMix will be the surviving entity.
WOW!!!MERGER!!!...MERGER!!! in the works! THIS IS GOING TO BE A COVID 19 TESTING PLAY! Boston Therapeutics (BTHE) is merging with NanoMix, Inc. NanoMix will be the surviving entity.
WOW!!!MERGER!!!...MERGER!!! in the works! THIS IS GOING TO BE A COVID 19 TESTING PLAY! Boston Therapeutics (BTHE) is merging with NanoMix, Inc. NanoMix will be the surviving entity.
SEC 8-k Filed
Agreement and Plan of Merger
On January 26, 2021, Boston Therapeutics, Inc., a Delaware corporation (the “Company”), BTHE Acquisition Inc., a California corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Nanomix, Inc., a California corporation (“Nanomix”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Nanomix, with Nanomix continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the “Merger”). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended. Nanomix has developed an advanced mobile Point-of-Care (POC) diagnostic system that can be used in performing a wide range of in vitro diagnostic tests in many environments. Our goal is to provide laboratory quality testing for time sensitive medical conditions, at the first point of contact that a patient has with the healthcare system, no matter where that occurs. The Nanomix eLab® system is CE Marked, a 510(k) is currently in process, and Emergency Use Applications (EUA) for COVID testing has been submitted to the FDA. We intend to market and sell this system for the detection and diagnosis of a variety of time sensitive medical conditions.....
https://www.sec.gov/Archives/edgar/data/1473579/000121390021006198/ea134438-8k_bostontherap.htm
This gonna be huge!
Nanomix is the leader in the development of mobile, affordable point-of-care diagnostics. We offer a handheld testing platform and assays that provide rapid, accurate, quantitative information for use in settings where time-to-diagnosis is critical for clinical decision-making and improved patient care.
Our goal is to expand access to quality healthcare by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote, or alternative settings.
We have tests available or under development to aid in the diagnosis of sepsis, acute kidney injury, and SARS-CoV-2. Results are returned in just 10 minutes.
https://nano.com/
This explains the uncommon trading activity of this dormant stock lately. LOL... NOT SELLING A SINGLE SHARE HERE.
Sorry no idea for I am not a chartist. Been holding for 5 years now. For companies like BTHE with great potential, it takes a ton of patience and a disciplined mindset to benefit the fullest it offers when the time comes. We currently have a dynamic young CEO who has strong connection in the Far East. Stay tune.
Up 91.9% something's brewing?
BTHE got some volume today. Nice close!
Cool! You're probably right that things might be different this time going forward as funding keep flowing per SEC filings and the new CEO's connections in the Far East. This is a test of patience and I got tons of it. LOL
Good point. Thanks! Btw First time poster here? If you don't mind me asking how did you find this company/stock? This is pretty much dormant/unknown but with great potential.
Cheng Chi-Heng "Conroy"
Interim CEO & CFO, Boston Therapeutics Inc
https://www.bloomberg.com/profile/person/4885548
New World Development Co Ltd
Appointed as an Executive Director in June 2010. Mr. Cheng is a member of the Executive Committee of the Board of Directors of the Company. He also acts as director of certain subsidiaries of the Group. Mr. Cheng is an executive director of Chow Tai Fook Jewellery Group Limited, a listed public company in Hong Kong. Mr. Cheng is a director of Chow Tai Fook (Holding) Limited and Chow Tai Fook Enterprises Limited, both are substantial shareholders of the Company. Mr. Cheng worked in Yu Ming Investment Management Limited from 1999 to 2000 as a corporate finance executive. He obtained his Bachelor of Arts Degree majoring in Economics from the University of Western Ontario, Canada in 1999. He is the son of Mr. Cheng Kar-Shing, Peter, the nephew of Dr. Cheng Kar-Shun, Henry and Mr. Doo Wai-Hoi, William, and the cousin of Dr. Cheng Chi-Kong, Adrian and Ms. Cheng Chi-Man, Sonia.
https://www.nwd.com.hk/corporate/about-NWD/leadership/mr-cheng-chi-heng
Cheng Chi-Heng "Conroy" is the nephew of Henry Cheng one of HONG KONG'S 50 RICHEST
Henry Cheng succeeded his late father, Cheng Yu-tung, as chairman of the family flagship firms Chow Tai Fook Jewellery and New World Development.
>>> At least nine family members work in the group's network of enterprises, including Henry Cheng's Harvard-educated children Adrian and Sonia.
>>> Adrian Cheng is the vice chairman of New World Development and Sonia Cheng is CEO of Rosewood Hotel Group, acquired by New World in 2011.
Henry and his father were the rare father and son winners of Hong Kong's Gold Bauhinia Medal for service to the city.
https://www.forbes.com/profile/henry-cheng-2/?sh=428d9614380b
It feels like BTHE is in good hands going forward :)
The new CEO is catching up on the company's SEC Filings lately. Maybe someone knows something good is coming as this sleeper suddenly awaken looking at the trading activity lately. I'm just excited that this is going again. Can't wait to find out clinical updates.
GLTA
Wishing RSCF and everyone here a Prosperous New Year!
Good Fortune RSCF!!!
mRNA vaccines spark innovation in logistics: Expert
Anjalee Khemlani·Senior Reporter
Thu, December 17, 2020, 7:02 AM PST·3 min read
The ultra-low temperature demands of the Pfizer (PFE) and BioNTech (BNTX) vaccine are paving a new path for vaccine delivery and storage.
While mRNA vaccines requires a smaller footprint for production than traditional vaccines, once they leave the production plant, there’s a whole new set of hurdles prompting logistics companies to adapt.
Planes have been retrofitted, GPS tracking has been authorized by the FAA, and states are buying large-volume freezers to meet the first generation of vaccine needs. The first several batches are not likely to sit on the shelves for long, experts say.
Food companies are no stranger to the vaccine temperatures — seafood and ice cream are among the foods that require the coldest storage. But the volume and speed required to get the vaccines from the plant to a person’s arm is unprecedented.
So why aren’t more food transportation companies involved? Because of cybersecurity concerns and a need for the federal government, which is overseeing logistics, to vet them.
“We’ve already seen attempts on intrusion into our logistics systems, into our agencies, into our partners,” said Brandon Daniels, president of global markets at Exiger.
Daniels is a consultant for the Department of Defense and Department of Homeland Security, both of which are involved in the vaccine logistics.
A majority of the delivery process has been figured out, but the administration of the vaccine rests on the states.
“We know how to get from ... [the plants] to an airport. I think we know how to get from the airport to a cold-storage fridge, and then I think we know how to implement at the designated major hospitals that are in each of those states. That’s where we are right now. That next phase of distribution out is still in the works,” Daniels said.
“There are courier services that have been engaged. Swift courier services, as an example ... They are traditionally known for rapid distribution of parcels. So there are courier services that are getting engaged in the distribution process,” he added.
Next generation transportation
Daniels believes that in addition to improving cold-chain logistics for the duration of the pandemic, new technologies are likely to take hold.
“Cryogenics companies will be a critical part of the supply chain,” he said. “Things like liquid that can be dry-frozen and unlocked and more advanced technologies are necessary for future distribution.”
For the next level of distribution, there are lots of possibilities to work through.
“We have to manage risk. There’s lot of technology that looks like its out of the movies,” Daniels said.
The ultra-cold storage units states have invested in are challenging to manufacture and ship, and there is also some degree of scarcity, he explained.
But for frozen liquid methods, it’s possible to have smaller cold storage units. And with the unmet global demand percolating, it’s especially important to focus on rural and poor infrastructure areas, he said.
“More advanced technologies are necessary for future distribution, especially with the efficacy numbers that Pfizer and Moderna have published,” Daniels said.
“The idea here needs to be that these technologies allow small, regional, not-as-well-funded areas to get access to these vaccines,” he said.
https://finance.yahoo.com/news/m-rna-vaccines-spur-innovation-in-logistics-expert-150201414.html